|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Indiana University School of Medicine |
|---|---|
| Information provided by (Responsible Party): | Indiana University ( Indiana University School of Medicine ) |
| ClinicalTrials.gov Identifier: | NCT00569842 |
Purpose
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
| Condition |
|---|
|
Leukemia Non-Hodgkin's Lymphoma Chronic Lymphocytic Leukemia Hodgkin's Disease Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Disorders Aplastic Anemia Chronic Myelogenous Leukemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Investigation of the Cylex® ImmuKnow® Assay |
None to be retained.
| Enrollment: | 45 |
| Study Start Date: | November 2007 |
| Estimated Study Completion Date: | November 2012 |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| observational |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
Inclusion Criteria:
Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
Contacts and Locations| United States, Indiana | |
| Indiana Universtiy Simon Cancer Center | |
| Indianapolis, Indiana, United States, 46202 | |
| Principal Investigator: | Sherif Farag, MD, PhD | Indiana University Simon Cancer Center |
More Information
| Responsible Party: | Indiana University ( Indiana University School of Medicine ) |
| ClinicalTrials.gov Identifier: | NCT00569842 History of Changes |
| Other Study ID Numbers: | 0710-11/ IUCRO-0207 |
| Study First Received: | December 5, 2007 |
| Last Updated: | March 30, 2012 |
| Health Authority: | United States: Institutional Review Board |
|
Anemia Anemia, Aplastic Hodgkin Disease Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Lymphoma Lymphoma, Non-Hodgkin Multiple Myeloma Neoplasms, Plasma Cell Myelodysplastic Syndromes Preleukemia Myeloproliferative Disorders |
Hematologic Diseases Bone Marrow Diseases Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hemorrhagic Disorders |
